- Email: [email protected]
Heinz karger prize
63
Announcements
Heinz Karger Prize 1987 'Monoclonal Antibodies for Diagnosis and Research in Pathology'; 1988, 1989, 1990 The prize awarded in memory of Heinz Karger, the well-known Basle publisher, for an outstanding scientific work, has in 1987 been conferred to: Dieter Bitter-Suermann and Jfirgen Roth (Basle, Switzerland) for their paper entitled 'Monoclonal Antibodies to Polysialic Acid Reveal Epitope Sharing between Invasive Pathogenic Bacteria, Differentiating Cells and Tumor Cells'. and to: D. Tibboel, J. H. Carel Meijers, Paul Klueck, Arthur W. M. van der Kamp, Fibo W. J. ten Kate, Ilse C. C. M. van Haperen-Heuts and Jan C. Molenaar (Rotterdam, Netherlands) for their paper entitled 'Monoclonal Antibodies for Diagnosis and Research in Enteric Nervous System Pathology'. The competition carries an award of SFr. 20,000; the Council of the Memorial Foundation has conferred an amount of SFr. 10,000 to either group of scientists. The Heinz Karger Memorial Foundation invites the submission of papers on the 1988 subject, 'Oncogenes in Cell Differentiation'. Conditions." Papers must represent original research work or a review of original research work performed by a scientist or a group of scientists. Manuscripts must not exceed 20 typewritten pages, including illustrations, tables and bibliography. Manuscripts marked 'Competition' have to reach the publisher, S. Karger AG, Basel, Allschwilerstrasse 10, CH-4009 Basel, not later than 28 February 1988. The manuscript must be typewritten on one side only, double-spaced, and is to be submitted in 5 copies, and in accordance with the instructions contained in the 'Rules for the Preparation of Manuscripts' which can be obtained free of charge from the publishers if the request is marked 'Competition'. Language." English, German or French. Publication: The winning paper will appear in English in one of the Karger journals. Competitors are requested to indicate the Karger journal in which they would like their paper to be published, Award." The award for the prize is SFr. 20,000. The Council of the Foundation will judge the papers and confer the prize. In 1989 no competition will take place. For 1990 the award granted will be SFr. 40,000; further information will be given in due time.
64
Rheumatoid Arthritis - - An Update on Mechanisms, Management and Future Drug Development 22/23 F e b r u a r y 1988, R e g e n t C r e s t H o t e l , L o n d o n Rheumatoid arthritis and related inflammatory diseases all]ict approximately 5% of the population and are associated with considerable morbidity. Howevcr, the mechanisms underlying this disease are poorly understood and our current treatment of such diseases is far from adequate. This mceting will discuss our current understanding of rheumatoid arthritis, its current lnanagemenl and the major areas of basic and clinical research that may hold the key to our future understanding and treatment. The conference should provide a valuable overview of both clinical and basic aspects of this important disease and will be of intcrest to health professionals, clinicians, scientists and others interested in any aspect of its aetiology and treatment. The meeting will also be of interest to individuals involved in the development of novel therapeutic agents for the future treatment of this and related inflammatory diseases.
New Treatments for Asthma 21/22 M a r c h 1988, R o y a l S o c i e t y o f M e d i c i n e , L o n d o n Asthma effects over 5% of the population and is becoming more prevalent and more severe, with an increasing mortality, despite an increase in anti-asthma drugs prescribed. There is now a great need for the advancement of new drugs and new approaches to therapy. The aim of this conference is to discuss future developments in our understanding of the mechanisms of this increasingly common disease.
Oxygen-Free Radicals in Health and Disease 18/19 A p r i l 1988, M a r r i o t t H o t e l , L o n d o n In the last few years, various free radical species have been identified as products of molecular oxygen. These naturally occurring products have been implicated in a wide range of both physiological and pthophysiological roles including natural defence and the tissue damage resulting from ischaemia in the cardiovascular system. This conference aims to provide a timely, comprehensive overview of the state-of-the art in free radical biology. Additionally, the meeting will provide a well-balanced programme of the current status of drugs affecting the oxygen-free radicals as novel therapeutic agents in a range of diseases. The conference should be of interest to all individuals investigating the possible role of free radicals in health and disease and should provide a useful update for those clinicians and scientists interested in the development of drugs interfering with the generation or action of oxygen-free radical species.
Migraine - - An Update on its Mechanisms, Management and Future Therapy 4/5 M a y 1988, R o y a l S o c i e t y o f M e d i c i n e , L o n d o n Headache is the most common symptom presenting to primary physicians of which up to 1 in 5 patients suffer from migraine. Despite the prevalence of migraine in the community, the underlying aetiology of this common disorder remains poorly understood. This meeting will attempt to bring together experts with an interest in migraine from a variety of disciplines to provide a unique update on many of the current important areas of clinical and basic research. It will additionally provide an overview on future drug developments for the management of this disease. The meeting should be of value to all health care professionals involved in the management of this disease as well as clinicians and scientists interested in the development of novel strategies for the future therapy of this disease.
Serotonin Explored - - What it Does and How it Can be Manipulated for Therapeutic Purposes 27/28 J u n e 1988, M a r r i o t t H o t e l , L o n d o n This symposium offers an overview of the current state of play in the field of serotonin research, with an international panel of speakers discussing what is known to date about serotonin's many actions in the body, and how they can be manipulated by compounds acting on serotonin for therapeutic purposes. The meeting will be of interest to all researchers in the field, whether working at the pharmacology or clinic level, within the industry or in academia/hospitals and to those outside the field with an interest in the future potential of drugs acting on serotonin.
Second Messenger Systems in Cellular Control - - Prospects for New Drugs? 11/12 J u l y 1988, R o y a l L a n c a s t e r H o t e l , L o n d o n F o r details on the a b o v e conferences please contact: Miss P e n n y R o b i n s o n , IBC Technical Services Ltd., B a t h H o u s e , 56 H o l b o r n V i a d u c t , L o n d o n E C 1 A 2 E X , U . K . (Tel: 01-236 4080/Tlx: 888870)
Announcements
Heinz Karger Prize 1987 'Monoclonal Antibodies for Diagnosis and Research in Pathology'; 1988, 1989, 1990 The prize awarded in memory of Heinz Karger, the well-known Basle publisher, for an outstanding scientific work, has in 1987 been conferred to: Dieter Bitter-Suermann and Jfirgen Roth (Basle, Switzerland) for their paper entitled 'Monoclonal Antibodies to Polysialic Acid Reveal Epitope Sharing between Invasive Pathogenic Bacteria, Differentiating Cells and Tumor Cells'. and to: D. Tibboel, J. H. Carel Meijers, Paul Klueck, Arthur W. M. van der Kamp, Fibo W. J. ten Kate, Ilse C. C. M. van Haperen-Heuts and Jan C. Molenaar (Rotterdam, Netherlands) for their paper entitled 'Monoclonal Antibodies for Diagnosis and Research in Enteric Nervous System Pathology'. The competition carries an award of SFr. 20,000; the Council of the Memorial Foundation has conferred an amount of SFr. 10,000 to either group of scientists. The Heinz Karger Memorial Foundation invites the submission of papers on the 1988 subject, 'Oncogenes in Cell Differentiation'. Conditions." Papers must represent original research work or a review of original research work performed by a scientist or a group of scientists. Manuscripts must not exceed 20 typewritten pages, including illustrations, tables and bibliography. Manuscripts marked 'Competition' have to reach the publisher, S. Karger AG, Basel, Allschwilerstrasse 10, CH-4009 Basel, not later than 28 February 1988. The manuscript must be typewritten on one side only, double-spaced, and is to be submitted in 5 copies, and in accordance with the instructions contained in the 'Rules for the Preparation of Manuscripts' which can be obtained free of charge from the publishers if the request is marked 'Competition'. Language." English, German or French. Publication: The winning paper will appear in English in one of the Karger journals. Competitors are requested to indicate the Karger journal in which they would like their paper to be published, Award." The award for the prize is SFr. 20,000. The Council of the Foundation will judge the papers and confer the prize. In 1989 no competition will take place. For 1990 the award granted will be SFr. 40,000; further information will be given in due time.
64
Rheumatoid Arthritis - - An Update on Mechanisms, Management and Future Drug Development 22/23 F e b r u a r y 1988, R e g e n t C r e s t H o t e l , L o n d o n Rheumatoid arthritis and related inflammatory diseases all]ict approximately 5% of the population and are associated with considerable morbidity. Howevcr, the mechanisms underlying this disease are poorly understood and our current treatment of such diseases is far from adequate. This mceting will discuss our current understanding of rheumatoid arthritis, its current lnanagemenl and the major areas of basic and clinical research that may hold the key to our future understanding and treatment. The conference should provide a valuable overview of both clinical and basic aspects of this important disease and will be of intcrest to health professionals, clinicians, scientists and others interested in any aspect of its aetiology and treatment. The meeting will also be of interest to individuals involved in the development of novel therapeutic agents for the future treatment of this and related inflammatory diseases.
New Treatments for Asthma 21/22 M a r c h 1988, R o y a l S o c i e t y o f M e d i c i n e , L o n d o n Asthma effects over 5% of the population and is becoming more prevalent and more severe, with an increasing mortality, despite an increase in anti-asthma drugs prescribed. There is now a great need for the advancement of new drugs and new approaches to therapy. The aim of this conference is to discuss future developments in our understanding of the mechanisms of this increasingly common disease.
Oxygen-Free Radicals in Health and Disease 18/19 A p r i l 1988, M a r r i o t t H o t e l , L o n d o n In the last few years, various free radical species have been identified as products of molecular oxygen. These naturally occurring products have been implicated in a wide range of both physiological and pthophysiological roles including natural defence and the tissue damage resulting from ischaemia in the cardiovascular system. This conference aims to provide a timely, comprehensive overview of the state-of-the art in free radical biology. Additionally, the meeting will provide a well-balanced programme of the current status of drugs affecting the oxygen-free radicals as novel therapeutic agents in a range of diseases. The conference should be of interest to all individuals investigating the possible role of free radicals in health and disease and should provide a useful update for those clinicians and scientists interested in the development of drugs interfering with the generation or action of oxygen-free radical species.
Migraine - - An Update on its Mechanisms, Management and Future Therapy 4/5 M a y 1988, R o y a l S o c i e t y o f M e d i c i n e , L o n d o n Headache is the most common symptom presenting to primary physicians of which up to 1 in 5 patients suffer from migraine. Despite the prevalence of migraine in the community, the underlying aetiology of this common disorder remains poorly understood. This meeting will attempt to bring together experts with an interest in migraine from a variety of disciplines to provide a unique update on many of the current important areas of clinical and basic research. It will additionally provide an overview on future drug developments for the management of this disease. The meeting should be of value to all health care professionals involved in the management of this disease as well as clinicians and scientists interested in the development of novel strategies for the future therapy of this disease.
Serotonin Explored - - What it Does and How it Can be Manipulated for Therapeutic Purposes 27/28 J u n e 1988, M a r r i o t t H o t e l , L o n d o n This symposium offers an overview of the current state of play in the field of serotonin research, with an international panel of speakers discussing what is known to date about serotonin's many actions in the body, and how they can be manipulated by compounds acting on serotonin for therapeutic purposes. The meeting will be of interest to all researchers in the field, whether working at the pharmacology or clinic level, within the industry or in academia/hospitals and to those outside the field with an interest in the future potential of drugs acting on serotonin.
Second Messenger Systems in Cellular Control - - Prospects for New Drugs? 11/12 J u l y 1988, R o y a l L a n c a s t e r H o t e l , L o n d o n F o r details on the a b o v e conferences please contact: Miss P e n n y R o b i n s o n , IBC Technical Services Ltd., B a t h H o u s e , 56 H o l b o r n V i a d u c t , L o n d o n E C 1 A 2 E X , U . K . (Tel: 01-236 4080/Tlx: 888870)